Valvular & structural heart diseaseRandomised controlled trial
Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial
- Randomised controlled trial
- investigator-initiated
- multicentre
- open-label
- non-inferiority
- 12 hospitals in the Netherlands
Authors' conclusion
In patients with coronary artery disease undergoing TAVI, deferral of PCI was non-inferior to PCI before TAVI for the 1-year composite of all-cause mortality, myocardial infarction, stroke, and major bleeding.
Study context
- Population
- Transcatheter aortic valve implantation (TAVI) patients with CAD
- Participants
- 466 patients
- Comparison
- Deferral of percutaneous coronary intervention (PCI) vs PCI before TAVI
- Deferraln = 233
- PCIn = 233reference
- Primary endpoint
- Composite of:
- All-cause mortality
- MI
- Stroke
- Major bleeding
- Follow-up
- 1 year
Primary result
As reported in the abstract
Each group vs PCIRate difference (95% CI)P value
Deferral
−1.7%(−9.5 to 6.2)
P = 0.0008 for non-inferiorityNon-inferiority margin 11 as printed, not drawn
Each group vs PCIHazard ratio (95% CI)P value
Deferral
0.89(0.62–1.28)
P = 0.68 for superiorityNon-inferiority margin 11 as printed, not drawn
Original publication
Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial. Lancet. Published 29 March 2026. doi:10.1016/s0140-6736(26)00308-9
Summarised from the published abstract; every number is checked against it